A Role for Chromosomal Microarray Testing in the Workup of Male Infertility.


Journal

The Journal of molecular diagnostics : JMD
ISSN: 1943-7811
Titre abrégé: J Mol Diagn
Pays: United States
ID NLM: 100893612

Informations de publication

Date de publication:
09 2020
Historique:
received: 04 10 2019
revised: 28 04 2020
accepted: 18 06 2020
pubmed: 3 7 2020
medline: 28 8 2021
entrez: 3 7 2020
Statut: ppublish

Résumé

Genetic analysis is a critical component in the male infertility workup. For male infertility due to oligospermia/azoospermia, standard guidelines recommend karyotype and Y-chromosome microdeletion analyses. A karyotype is used to identify structural and numerical chromosome abnormalities, whereas Y-chromosome microdeletions are commonly evaluated by multiplex PCR analysis because of their submicroscopic size. Because these assays often require different Vacutainer tubes to be sent to different laboratories, ordering is prone to errors. In addition, this workflow limits the ability for sequential testing and a comprehensive test result. A potential solution includes performing Y-microdeletion and numerical chromosome analysis-the most common genetic causes of oligospermia/azoospermia-by chromosomal microarray (CMA) and reflexing to karyotype as both assays are often offered in the cytogenetics laboratory. Such analyses can be performed using one sodium heparin Vacutainer tube sample. To determine the effectiveness of CMA for the detection of clinically significant Y-chromosome microdeletions, 21 cases with known Y microdeletions were tested by CytoScan HD platform. CMA studies identified all known Y-chromosome microdeletions, and in 11 cases (52%) identified additional clinically important cytogenetic anomalies, including six cases of 46, XX males, one case of isodicentric Y, two cases of a dicentric Y, and three cases of terminal Yq deletions. These findings demonstrate that this testing strategy would simplify ordering and allow for an integrated interpretation of test results.

Identifiants

pubmed: 32615168
pii: S1525-1578(20)30372-X
doi: 10.1016/j.jmoldx.2020.06.009
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1189-1198

Informations de copyright

Copyright © 2020 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Auteurs

Kelsey J McIntyre (KJ)

Department of Pathology, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts; Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, Minnesota.

Elissa Murphy (E)

Laboratory for Molecular Medicine, Partners HealthCare Personalized Medicine, Cambridge, Massachusetts.

Lauren Mertens (L)

Department of Pathology, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts.

Adrian M Dubuc (AM)

Department of Pathology, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts.

Ruth A Heim (RA)

Division of Integrated Genetics, LabCorp, Westborough, Massachusetts.

Heather Mason-Suares (H)

Department of Pathology, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts; Laboratory for Molecular Medicine, Partners HealthCare Personalized Medicine, Cambridge, Massachusetts. Electronic address: hmason-suares@bwh.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH